Inhibitory effects of three-component hybrid liposomes containing cationic lipids without drugs on the growth of human renal tumor cells in vitro

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 9, 2008, Pages 1816-1817

  Umebayashi, Masayo ^a   Matsumoto, Yoko ^a   Ueoka, Ryuichi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Liposome; Renal tumor

Indexed keywords

DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; ETHANOLAMINE; HYBRID LIPOSOME; LIPOSOME; O,O' DITETRADECANOYL N (ALPHA TRIMETHYLAMMONIOACETYL)DIETHANOLAMINE CHLORIDE; POLIDOCANOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL; TUMOR CELL;

ANIMALS; CARCINOMA, RENAL CELL; CATIONS; CELL LINE, TUMOR; DRUG CARRIERS; HEMOLYSIS; HUMANS; KIDNEY NEOPLASMS; LIPIDS; LIPOSOMES; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE;

EID: 51449104025     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.1816     Document Type: Article

References (17)

1. Rinehart J. J., Young D., Laforge J., Colborn D., Neidhart J. A., Cancer Res., 47, 2481-2485 (1987).
2. Motzer R. J., Bacik J., Murphy B. A., Russo P., Mazumder M., J. Clin. Oncol., 20, 289-296 (2002).
3. Reu F. J., Bae S. I., Cherkassky L., Leaman D. W., Lindner D., Beaulieu N., Macleod A. R., Borden E. C., J. Clin. Oncol., 24, 3771-3779 (2006).
4. Nakanishi H., Mizutani Y., Kawauchi A., Ukimura O., Shiraishi T., Hatano M., Mizuno M., Yoshida J., Miki T., Clin. Cancer Res., 9, 1129-1135 (2003).
5. Felgner P. L., Gadek T. R., Holm M., Roman R., Chan H. W., Wenz M., Northrop J. P., Ringold G. M., Danielsen M., Proc. Natl. Acad. Sci. U.S.A., 84, 7413-7417 (1987).
6. Ueoka R., Moss R. A., Swarup S., Matsumoto Y., Strauss G., Murakami Y., J. Am. Chem. Soc., 107, 2185-2186 (1985).
7. Ueoka R., Matsumoto Y., Moss R. A., Swarup S., Sugii A., Harada K., Kikuchi J., Murakami Y., J. Am. Chem. Soc., 110, 1588-1595 (1988).
8. Kitamura I., Kochi M., Matsumoto Y., Ueoka R., Kuratsu J., Ushio Y., Cancer Res., 56, 3986-3992 (1996).
9. Matsumoto Y., Kato T., Iseki S., Suzuki H., Nakano K., Iwahara M., Ueoka R., Bioorg. Med. Chem. Lett., 9, 1937-1940 (1999).
10. Kanno A., Terada Y., Tsuzaki K., Matsumoto Y., Ueoka R., Drug Delivery System, 14, 37-42 (1999).
11. Ueoka R., Matsumoto Y., Ichihara H., Kiyokawa T., Am. Chem. Soc. Books, 2002, 177-189 (2002).
12. Matsumoto Y., Iwamoto Y., Ueoka R., Int. J. Cancer, 115, 377-382 (2005).
13. Nagami H., Nakano K., Ichihara H., Matsumoto Y., Ueoka R., Bioorg. Med. Chem. Lett., 16, 782-785 (2006).
14. Matsumoto Y., Kato T., Suzuk H., Hirose S., Naiki Y., Hirashima M., Ueoka R., Bioorg. Med. Chem. Lett., 10, 2617-2619 (2000).
15. An electron micrograph was obtained by means of negative-staining techniques with ammonium molybdate using electron microscope (JEOL JEM100S).
16. Huang S. K., Lee K. D., Hong K., Friend D. S., Papahadjopoulos D., Cancer Res., 52, 5135-5143 (1992).
17. Ishiyama M., Shiga M., Sasamoto K., Mizoguchi M., Chem. Pharm. Bull., 41, 1118-1122 (1993).